Briefing on the Acquisition of Wako Pure Chemical Industries, Ltd
Main Questions and Answers

Q1: How many years do you expect it takes to recover the investment of JPY 154.7 billion?
A1: It would take over 10 years, considering the Wako’s EBITDA of JPY 12.3 billion estimated in this fiscal year. However, we are expecting earlier recovery as the synergies in broad area can be anticipated. The EBITDA can be broken down into Wako’s businesses; laboratory chemicals of about 40%, clinical diagnostics reagents of about 40 %, and specialty chemicals of the rest.

Q2: How much do you expect the synergistic effect between Wako and Fujifilm?
A2: We expect the sale and operating profit of Wako in the fiscal year ending March 31, 2022 as JPY 100 billion and JPY 18 billion, respectively. The amount of operating income is expected to grow by about JPY 10 billion compared with that of the last fiscal year, we will achieve about the half of this growth by combining technologies of Wako and Fujifilm in the regenerative medicine business field. The JPY 3 billion out of the remaining JPY 5 billion can be achieved by such measures as sharing each other’s sales network in the fields of laboratory chemicals, clinical diagnostics reagents and specialty chemicals, and cost reduction of laboratory chemicals by Fujifilm’s synthesis technologies. We expect the rest of about JPY 2 billion to be achieved by such measures as joint procurement of raw materials and decrease in capital expenditure by the effective use of facilities and others.

(End)